Latest News

Ario Pharma Commences Efficacy Trial of TRPV1 Inhibitor in Chronic Idiopathic Cough.

Cambridge, UK, 09 July 2014: Ario Pharma Ltd, the biopharmaceutical company developing innovative new treatments for respiratory disease, announced today that it has commenced a Phase IIa study of its oral TRPV1 antagonist, XEN-D0501, for the treatment and prevention of cough in patients with chronic idiopathic cough (CIC). Approximately 20 patients will be enrolled into the...


Apica Cardiovascular sold to Thoratec for $75m.

3rd July 2014, Dublin Ireland. Seroba Kernel Life Sciences, a European life science venture capital company based in Dublin, is pleased to announce the sale of its investee company, Apica Cardiovascular, to Thoratec Corporation (NASDAQ: THOR) for $75m. Apica has developed an innovative transapical access and closure system that can simplify and standardize the technique used...


First Patient Enrolled in US Study of Novate’s Sentry IVC Filter.

Galway, Ireland. 22 September 2014 – Seroba Kernel investee company, Novate Medical, announced today that Souheil Saddekni MD, Professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham has enrolled the first patient in the SENTRY IDE Study. The SENTRY study is a prospective, single-arm, multi-centre study designed to evaluate the safety and...


< back to home page